Literature DB >> 3110071

Recurrent erysipelas: predisposing factors and costs of prophylaxis.

C Jorup-Rönström, S Britton.   

Abstract

After an average follow-up time of three years, recurrent erysipelas was observed in 29% of 143 patients admitted primarily with erysipelas. Nineteen patients (13%) had two or more recurrences during this period. The predisposing factor with the highest recurrence rate was venous insufficiency. Regular prophylaxis with phenoxymethylpenicillin (or erythromycin in penicillin allergics) after the second recurrence may be cost-effective. This antibiotic prophylaxis is only recommended in patients with predisposing factors who have suffered severe attacks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110071     DOI: 10.1007/bf01650206

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Group A -hemolytic streptococcemia. Bacteriologic and clinical study of 44 cases.

Authors:  K A Hable; C Horstmeier; A D Wold; J A Washington
Journal:  Mayo Clin Proc       Date:  1973-05       Impact factor: 7.616

2.  Prophylactic antibiotics in recurrent erysipelas.

Authors:  S Bitnun
Journal:  Lancet       Date:  1985-02-09       Impact factor: 79.321

3.  Prophylactic antibiotics in recurrent erysipelas.

Authors:  P Thind
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

4.  Prophylactic antibiotics in erysipelas.

Authors:  T Duvanel; Y Mérot; M Harms; J H Saurat
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

5.  The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas.

Authors:  C Jorup-Rönström; S Britton; A Gavlevik; K Gunnarsson; A C Redman
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

6.  [Therapy and prophylaxis of recurrent erysipelas (author's transl)].

Authors:  A Ziebart-Schroth
Journal:  Med Klin       Date:  1976-07-09
  6 in total
  18 in total

1.  Virulence properties of erysipelas-associated group A streptococci.

Authors:  A Norrby; B Eriksson; M Norgren; C J Rönström; A C Sjöblom; K Karkkonen; S E Holm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

Review 2.  Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.

Authors:  Abraham Pulido-Cejudo; Mario Guzmán-Gutierrez; Abel Jalife-Montaño; Alejandro Ortiz-Covarrubias; Jose Luis Martínez-Ordaz; Héctor Faustino Noyola-Villalobos; Luis Mauricio Hurtado-López
Journal:  Ther Adv Infect Dis       Date:  2017-08-31

3.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

Review 4.  Antimicrobial prophylaxis in adults.

Authors:  Mark J Enzler; Elie Berbari; Douglas R Osmon
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

Review 5.  Cellulitis and erysipelas.

Authors:  Andrew D Morris
Journal:  BMJ Clin Evid       Date:  2008-01-02

6.  Antibiotic prophylaxis in recurrent erysipelas.

Authors:  A C Sjöblom; B Eriksson; C Jorup-Rönström; K Karkkonen; M Lindqvist
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

7.  Cellulitis and erysipelas: prevention.

Authors:  Choon Chiat Oh
Journal:  BMJ Clin Evid       Date:  2015-11-18

Review 8.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

9.  Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial.

Authors:  Kim Thomas; Angela Crook; Katharine Foster; James Mason; Joanne Chalmers; John Bourke; Adam Ferguson; Nick Level; Andrew Nunn; Hywel Williams
Journal:  Br J Dermatol       Date:  2011-12-06       Impact factor: 9.302

10.  Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg.

Authors:  Kim S Thomas; Neil H Cox; Boki S P Savelyich; Debbie Shipley; Sarah Meredith; Andrew Nunn; Nick Reynolds; Hywel C Williams
Journal:  Trials       Date:  2007-01-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.